Daiichi Sankyo pipeline

Chugai's development pipeline is categorized to Oncology, Neuroscience, Hematology, Ophthalmology...

20, 2015 /PRNewswire/ -- Today, Chugai Pharma USA Inc. (CPUSA), a wholly-owned ... and early clin...

Description/ Summary: Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antib...

Chugai Pharmaceutical's own in-house development pipeline has one of the strongest line-ups in Ja...

As a drug manufacturer and a pioneer in biotechnological and pharmaceutical research, Chugai is a...